A recent Nature news piece examines the emerging science of mitochondrial transfer between cells and asks whether this process could be leveraged to treat cancer and other diseases. Among the leading experts in the field interviewed for this news piece is LIT scientist, Dr. Jeremy Baldwin, whose recent publication brought new attention to the discipline of organelle medicine.
We’re thrilled to have Prof. Carmen Gerlach join our team. She has been dedicated to understanding diversification within CD8+ T cell responses for 20 years. Her new research division “Tailored T-Cell Diversity” works on T cell immunotherapy of cancer and inflammatory diseases.
The daily newspaper Handelsblatt ranked iOmx as one of the five most promising biotech startups in Germany. iOmx was founded by Prof. Philipp Beckhove, Scientific Director of the Leibniz Institute for Immunotherapy (LIT), and Dr. Nisit Kandelwal in 2016.
A group of 18 PhD students of the Leibniz Institute for Immunotherapy (LIT) attended this year’s PhD retreat in the Bavarian Forest.
We are excited to welcome Dr. Leo Scheller to our team. He will head the new research group “Structural Biochemistry” at the LIT, which develops synthetic receptors and protein therapeutics to improve the safety and efficacy of immunotherapies.
“Book a Scientist” is a conversation format in which interested parties can “book” 25-minute one-on-one conversations with Leibniz scientists on fixed topics according to the speed dating principle.
Over 30 interested citizens of Regensburg, along with members of the CSU parliamentary group and Mayor Dr. Astrid Freudenstein, visited the Leibniz Institute for Immunotherapy on Tuesday, March 25.
The LIT is expanding its clinical cooperations and welcomes several new LIT Cooperation Groups with their staff. This cooperational format aims to foster scientific synergies and clinical translation with groups that address complementary clinical topics in immunomedicine.
Dr. Dr. Roland Schelker, head of the newly formed Translation Group “T-Cell Fitness” at the LIT and hematology/oncology medical specialist at the University Hospital Regensburg, receives a 75,000 USD G-Rex® Grant by ScaleReady LLC. Pedro Noronha, Research Technician in the LIT Division of Functional Immune Cell Modulation, was intensively involved in the grant application process.
Researchers at the University Hospital Regensburg and the Leibniz Institute for Immunotherapy (LIT) are embarking on an innovative project, ESOSTEM155, aimed at transforming T cell-based cancer therapies. This initiative has been awarded a two-year grant of 460,000 EUR from the National Strategy for Gene and Cell-based Therapies (GCT) funding program.
